Is Fezonetam Tablets available for purchase in the country?

Fezolinetant is a new drug targeting vasomotor symptoms of menopause and is a neurokinin 3 (NK3) receptor antagonist. This drug is designed to relieve moderate to severe hot flashes and night sweats caused by hormone fluctuations during menopause, helping women improve sleep disturbance, anxiety and reduced quality of life caused by hot flashes. Menopausal hot flashes are a symptom experienced by the vast majority of menopausal women and are traditionally treated with hormone replacement therapy (HRT), but some patients are unable to use hormone medications due to hormone-related risks. The emergence of filazonatant provides a new non-hormonal treatment option for these patients.

By blockingNK3 receptors, Fezonatant regulates the neural pathways that control body temperature in the central nervous system, fundamentally reducing the frequency and intensity of hot flashes without affecting hormone levels, thus avoiding the potential risks of hormone therapy. Currently, fezonatant has been approved in many countries for the treatment of vasomotor symptoms of menopause, and clinical data shows that its safety and efficacy are both good.

However, as far as the domestic market is concerned, fezonatant has not yet been officially approved for marketing, nor has it been included in the medical insurance system, resulting in domestic patients being unable to purchase it through local regular channels. Although some patients try to obtain the drug through purchasing agents or overseas drug purchase channels, due to drug safety, quality assurance and legal compliance issues, officials do not recommend the use of drugs through informal channels. At the same time, imported drugs may be risky during transportation and storage, and after-sales service cannot be guaranteed. This is something that patients need to pay special attention to when choosing.

With the continuous improvement of China's pharmaceutical supervision and the introduction of more innovative drugs, Fezonastat is expected to be launched in the country in the future. By then, patients can purchase it through regular channels and use it rationally under the guidance of doctors to improve the safety and effectiveness of treating menopausal hot flashes.

Reference materials:https://www.veozah.com/